REGENXBIO Inc. (Nasdaq: RGNX) shares declined on Wednesday following the release of interim data for its Duchenne muscular dystrophy therapy trial. The stock slide is attributed to mixed signals in the market that led to selling pressure, despite the positive clinical outcomes reported in the Phase I/II AFFINITY DUCHENNE trial for RGX-202. Clinical data indicated that participants in the pivotal dose group exceeded external controls in functional measures after one year of treatment. Safety remains a strong point, with no serious adverse events reported and stable cardiac MRI and liver safety profiles. While the progress positions RGX-202 as a potential best-in-class treatment, the market reaction reflects a cautious stance ahead of pivotal topline data expected in Q2 2026. This update highlights a disconnect between promising clinical milestones and immediate investor sentiment.
Sign up free to access this content
Create Free Account